February 27, 2017 10:14 AM EST

Gerngross’ Adimab hands over RSV antibodies to Arsanis, a biotech he co-founded in Vienna

Arsalan Arif

Founder

Tillman Gerngross is taking a group of antibodies identified by his discovery group Adimab and handing them over to Arsanis, a Vienna-based biotech he …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gerngross’ Adimab hands over RSV antibodies to Arsanis, a biotech he co-founded in Vienna

Arsalan Arif

Founder

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Two GSK trials with long-acting drug in chronic rhinosinusitis hit primary endpoints

Pfizer details results from failed Phase 3 trial of Duchenne muscular dystrophy gene therapy

Novo Nordisk files 18 lawsuits against GLP-1 compounders in 44 days

Updated: Lundbeck makes $2.6B cash move for Longboard a month after starting Phase 3 in Dravet syndrome

Novartis used a PRV to speed Kisqali's latest indication, FDA says

Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies

Gern­gross’ Adimab hands over RSV an­ti­bod­ies to Ar­sa­nis, a biotech he co-found­ed in Vi­en­na

Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Gerngross’ Adimab hands over RSV antibodies to Arsanis, a biotech he co-founded in Vienna